Rhapsido
Payments companies reported to CMS as associated with Rhapsido. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rhapsido, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rhapsido
These are the largest totals companies reported as associated with Rhapsido. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Russell Settipane | Middletown, RI | Allergy & Immunology | $24,217.96 |
| Michael Blaiss | Roswell, GA | Allergy & Immunology | $22,131.26 |
| Priya Bansal | Saint Charles, IL | Allergy & Immunology | $21,122.59 |
| Naiem Issa | Vienna, VA | Dermatology | $19,224.34 |
| Giselle Mosnaim | Chicago, IL | Allergy & Immunology | $13,486.57 |
| April Armstrong | Los Angeles, CA | Dermatology | $12,300.00 |
| Todd Schlesinger | Charleston, SC | Dermatology | $11,735.00 |
| Robert Sporter | New York, NY | Allergy & Immunology | $11,569.46 |
| Marcjonathan Serota | Littleton, CO | Dermatology | $11,337.03 |
| David Cotter | Las Vegas, NV | Dermatology | $11,269.28 |
Prescribed Rhapsido?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.